Galderma Fails to Block Lupin’s Oracea Copy During Patent Appeal

A federal judge rejected Galderma Laboratories LP’s emergency request to block Lupin Ltd.’s launch of an Oracea rosacea treatment copy during the appeal of his March ruling that the generic doesn’t infringe two Galderma patents.

Judge Stephanos Bibas, sitting by designation from the Third Circuit, denied Galderma’s emergency motion for an injunction pending appeal, saying it recycled “many of the same arguments that I found thoroughly unconvincing” during January’s bench trial, according to an opinion issued Thursday in the US District Court for the District of Delaware.

• Galderma and TCD Royalty Sub LP—the DRI Healthcare Trust unit that exclusively licenses ...